Clinical Trial Update: A Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 study of Rituximab (MabThera/Rituxan) in patients with relapsed centroblastic-centrocytic non-Hodgkin lymphoma has completed, with results posted in 201…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• MabThera/Rituxan (Rituximab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2014-11-04